Adakveo (crizanlizumab) PRegnancy outcomes Intensive Monitoring (PRIM)

18/02/2021
26/03/2026
EU PAS number:
EUPAS39412
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Protocol_SEG101 PRIM_10July2020_clean_Redacted

English (364.16 KB - PDF) View document
Study results
Study report
Abstract of study report

CSEG101A2404 Report Component Report Body Abstract_Redacted.pdf

English (67.76 KB - PDF) View document
Study report

CSEG101A2404 Report Component- Report Body (1).pdf

English (339.64 KB - PDF) View document
Other information